PharmaSecure advances to phase two of “The Grand Challenges in TB Control” program in India, sponsored by The Gates Foundation and USAID

Grand Challenge in TB Control

PharmaSecure advances to phase two of “The Grand Challenges in TB Control” program in India, sponsored by The Gates Foundation and USAID

Transforming healthcare delivery in emerging markets by tracking the distribution of medicines and understanding the behavior and outcomes of the patients who use them

New Delhi, India (August 10, 2015) – PharmaSecure, a leading global provider of brand protection and customer engagement solutions, has been one of four organizations selected to advance to phase two of “The Grand Challenges in TB Control” program, sponsored by the Gates Foundation and USAID, to find novel solutions to improve the health outcomes of patients with Tuberculosis (TB). Results from the first phase of the program in India showed that patients who were enrolled in PharmaSecure’s psConnect™ patient management platform had a 60% increase in reported adherence to the TB drug regimen over non-enrolled patients.In phase one of the program, PharmaSecure enrolled patients in their psConnect™ patient management and engagement platform to help TB patients complete their treatment regimen using customized reminders and incentives. Those patients who were enrolled in PharmaSecure’s psConnect™ patient management platform received either a reminder SMS, automated phone calls, or a direct call from a PharmaSecure patient liaison. A typical TB treatment regimen requires daily doses of antibiotics for 3-9 months and missed doses can lead to complications in treatment and may lead to drug resistance, risking lives and wasting public health funding. TB is second only to HIV/AIDS as the greatest killer worldwide due to a single infectious agent. In 2013, 9 million people fell ill with TB and 1.5 million died from the disease according to the World Health Organization. In India alone there were over 2 million incidences of TB in 2013 and an estimated 40% of the population is infected with TB bacteria, the vast majority of which is latent rather than active TB.

Phase two of the program will involve expanding the scope to specific geographies, to not only understand the impact on patient adherence, but also the drivers of adherence including the circumstances that a patient finds themselves in (e.g., no access to running water) and the challenges they face in adhering to treatment (e.g., lack of time).

About PharmaSecure

PharmaSecure was founded in the United States in 2007 with a vision to protect medicines against counterfeiting by uniquely identifying each medicine pack sold. PharmaSecure and ProductSecure mobile technology solutions protect products across industries from counterfeiting while providing intelligence on their distribution, use in emerging markets, and improving engagement with consumers of those products. Till date, PharmaSecure has protected over 1.5 billion packages for 50 companies through serialization for brand protection, regulatory compliance, patient engagement and market intelligence.

About “The Grand Challenges in TB Control” Program

The Grand Challenges in TB Control (GC-TBC) is an initiative to encourage and nurture innovations that will help alleviate the problem of TB in India. IKP Knowledge Park (IKP), the United States Agency for International Development (USAID), the Biotechnology Industry Research Assistance Council (BIRAC), and the Bill and Melinda Gates Foundation (BMGF) are working together to identify, fund, and nurture technology driven solutions that will assist TB control.

Share:
About Us

Founded with a vision to protect medicines against counterfeiting, PharmaSecure® solutions protect products across industries, help manufacturers meet global regulatory serialization requirements, and enable innovative patient and consumer engagement programs. learn more...

Get In Touch
PharmaSecure India - Sales
505, 5th Floor, Timmy Arcade,
Makwana Road, Marol,
Andheri (East) Mumbai – 400059 (India)
P:+91 22 6755 6011
PharmaSecure Inc.
@ The Centre for Social Innovation
Suite 325-254
601 West 26th Street
New York, New York 10001, USA
P:+1 866-350-4450 ext.804